These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34125179)

  • 61. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
    Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
    Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
    Furukawa K; Kawasaki G; Yoshida T; Umeda M
    Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.
    Takashima Y; Kawaguchi A; Sato R; Yoshida K; Hayano A; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Nakano M; Ogawa S; Tashiro K; Yamanaka R
    Sci Rep; 2019 Jul; 9(1):10004. PubMed ID: 31292525
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
    Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice.
    Li S; Tajiri K; Murakoshi N; Xu D; Yonebayashi S; Okabe Y; Yuan Z; Feng D; Inoue K; Aonuma K; Shimoda Y; Song Z; Mori H; Huang H; Aonuma K; Ieda M
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572655
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
    Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
    Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
    Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.
    Zhao Q; Guo J; Zhao Y; Shen J; Kaboli PJ; Xiang S; Du F; Wu X; Li M; Wan L; Li X; Wen Q; Li J; Zou C; Xiao Z
    Epigenomics; 2020 Dec; 12(24):2155-2171. PubMed ID: 33337915
    [No Abstract]   [Full Text] [Related]  

  • 72. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
    Kinch A; Sundström C; Baecklund E; Backlin C; Molin D; Enblad G
    Leuk Lymphoma; 2019 Feb; 60(2):376-384. PubMed ID: 30033844
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients.
    Rajabian Z; Kalani F; Taghiloo S; Tehrani M; Rafiei A; Hosseini-Khah Z; Hosseini V; Ajami A
    Iran J Immunol; 2019 Mar; 16(1):62-70. PubMed ID: 30864556
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
    Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
    Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ASO Author Reflections: Clinical Implications of Programmed Death-Ligand 2 (PD-L2) Expression as an Independent Prognostic Marker in Lung Adenocarcinoma: Different Characteristics of PD-L2-Positive Patients from Those with Programmed Death-Ligand 1.
    Takamori S; Takada K; Maehara Y
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):668-669. PubMed ID: 31368016
    [No Abstract]   [Full Text] [Related]  

  • 80. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.